acalabrutinib
Phase 3- Indications
- Chronic lymphocytic leukemia, Mantle cell lymphoma, B-cell malignancies
Company intelligence / Profile preview
Acerta Pharma
Oss, Netherlandsacerta-pharma.com ↗
- Ownership
- Private
- Employees
- ~200
- Development stage
- Phase 3
01
Overview
Acerta Pharma's flagship drug Calquence (acalabrutinib) has been approved by the FDA for the treatment of mantle cell lymphoma (2017) and chronic lymphocytic leukemia (2019). The drug is now used to treat tens of thousands of patients worldwide and generated more than $2 billion in revenue in 2022[4][5].
- Therapeutic areas
- OncologyHematology
- Modalities
- Small molecule drugsMonoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Ascentage PharmaForty Seven Inc.
Beyond the preview
Go deeper on Acerta Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Acerta Pharma.